Erenumab
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Erenumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Erenumab is a CGRP-receptor-targeting monoclonal antibody internationally approved for migraine prevention (episodic and chronic), though it is not currently marketed in Norway per this evidence pack. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, a distinct ICHD-3 subtype, but currently 0 clinical trials and 20 publications support this specific direction — and none of those publications are trials that specifically enrolled this aura subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (episodic/chronic) — internationally approved; no Norway market data on file |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured MOA field. Based on available evidence, however, erenumab is a monoclonal antibody that blocks the calcitonin gene-related peptide (CGRP) receptor, thereby inhibiting CGRP-mediated vasodilation and neurogenic inflammation within the trigeminovascular system — the pathway underlying its approved use in general migraine prevention.
The original indication (general migraine prevention) and the predicted indication (migraine with brainstem aura, formerly "basilar-type migraine") converge on the same CGRP pathway. Migraine with brainstem aura is a distinct ICHD-3 subtype whose pathophysiology involves posterior circulation (vertebrobasilar) vascular regulation. Mechanistically, CGRP receptor blockade could plausibly modulate vascular tone in this specific territory, offering a rationale for extending erenumab's use to this subtype.
However, patients with migraine with aura — including brainstem aura — were explicitly excluded from the major pivotal trials (STRIVE, ARISE) that established erenumab's efficacy for general migraine prevention. This means existing efficacy and safety data for migraine "with/without aura" (a broader, non-brainstem population) cannot be directly extrapolated to this higher-risk subtype. Given the elevated vascular risk historically associated with brainstem aura, this prediction is mechanistically plausible but safety-unproven for the specific target population.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34928306 | 2022 | RCT (post-hoc subgroup) | JAMA Neurology | Secondary analysis of RCTs assessing erenumab safety/efficacy in migraine with vs. without aura; addresses elevated vascular risk in aura patients |
| 32867533 | 2021 | RCT | Cephalalgia | Erenumab did not alter cerebral vasomotor reactivity or endothelial function in migraine without aura |
| 30360965 | 2018 | RCT (Phase 3b) | Lancet | Randomised, double-blind, placebo-controlled trial: erenumab effective/tolerable in treatment-resistant episodic migraine |
| 37012858 | 2023 | Systematic Review | Int Immunopharmacol | Systematic review confirming erenumab efficacy in episodic/chronic migraine prophylaxis |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Foundational review of CGRP's role in migraine pathophysiology, underpinning CGRP-antibody rationale |
| 41888647 | 2026 | Cohort (REFORM study) | J Headache Pain | Longitudinal study of erenumab's effect on migraine aura frequency specifically — most directly relevant to this indication |
| 40275185 | 2025 | Cohort (biomarker) | J Headache Pain | Plasma suPAR (elevated in migraine with aura) associated with erenumab treatment response |
| 36942409 | 2023 | Cohort | Headache | Post hoc pooled analysis of cardiovascular safety in migraine patients with/without aura on long-term erenumab |
| 35151970 | 2022 | Cohort | Clin Neurol Neurosurg | Real-world effectiveness/safety of erenumab in treatment-resistant chronic migraine (Croatia) |
| 32359106 | 2020 | Case series | Headache | Erenumab efficacy on comorbid cluster headache in migraine patients — related CGRP-pathway indication |
Norway Market Information
Currently not marketed in Norway; no market authorization data available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale (CGRP receptor blockade) is plausible, and one directly relevant study (REFORM, PMID 41888647) examined aura frequency under erenumab treatment. However, no clinical trials specifically enrolled migraine-with-brainstem-aura patients — pivotal trials explicitly excluded aura populations — and this subtype carries an elevated vascular risk profile that has not been safety-validated for CGRP receptor blockade in the posterior circulation.
To proceed, the following is needed:
- Regulatory safety label data (warnings, contraindications) — currently a blocking data gap preventing S1 safety assessment
- Formal MOA documentation from DrugBank/regulatory sources
- Dedicated clinical evidence (trial or case series) enrolling patients specifically diagnosed with migraine with brainstem aura
- Cardiovascular/posterior-circulation vascular risk assessment specific to this subtype
- Confirmation of Norway market authorization status, should commercial availability be pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.